Director’s Bold Move: Major Investment in SeaStar Medical Holding
TipRanks (Thu, 27-Feb 9:06 PM ET)
SeaStar Medical Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market
Globe Newswire (Mon, 3-Feb 4:05 PM ET)
SeaStar Medical Announces $6 Million Registered Direct Offering Priced At-the-Market
Globe Newswire (Fri, 31-Jan 8:00 AM ET)
SeaStar Medical Adds Fifth Hospital Customer for QUELIMMUNE
Globe Newswire (Mon, 27-Jan 8:00 AM ET)
SeaStar Medical Activates 15th Site for its Adult Acute Kidney Injury Pivotal Trial
Globe Newswire (Wed, 22-Jan 7:30 AM ET)
Globe Newswire (Mon, 13-Jan 8:30 AM ET)
SeaStar Medical Begins Shipping QUELIMMUNE to a Fourth Hospital Customer
Globe Newswire (Wed, 8-Jan 8:30 AM ET)
SeaStar Medical Activates 14th Hospital for its Adult AKI Pivotal Trial
Globe Newswire (Mon, 23-Dec 7:00 AM ET)
Globe Newswire (Mon, 16-Dec 9:00 PM ET)
Globe Newswire (Wed, 11-Dec 6:30 AM ET)
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.
Seastar Medical Holding trades on the NASDAQ stock market under the symbol ICU.
As of March 4, 2025, ICU stock price declined to $1.70 with 159,236 million shares trading.
ICU has a beta of 0.24, meaning it tends to be less sensitive to market movements. ICU has a correlation of 0.00 to the broad based SPY ETF.
ICU has a market cap of $12.21 million. This is considered a Sub-Micro Cap stock.
Last quarter Seastar Medical Holding reported $68,000 in Revenue and -$1.10 earnings per share. This fell short of revenue expectation by $-2,000 and exceeded earnings estimates by $.03.
The top ETF exchange traded funds that ICU belongs to (by Net Assets): VXF.
ICU has underperformed the market in the last year with a return of -91.4%, while the SPY ETF gained +13.9%. In the last 3 month period, ICU fell short of the market, returning -28.3%, while SPY returned -4.2%. However, in the most recent 2 weeks ICU has outperformed the stock market by returning -5.0%, while SPY returned -5.4%.
ICU support price is $1.64 and resistance is $1.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ICU shares will trade within this expected range on the day.